Author:
Dengel Lynn T.,Norrod Allison G.,Gregory Briana L.,Clancy-Thompson Eleanor,Burdick Marie D.,Strieter Robert M.,Slingluff Craig L.,Mullins David W.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology,Immunology,Immunology and Allergy
Reference45 articles.
1. Malignant melanoma in situ: an oxymoron whose time has come;Mihm;Hum Pathol,1998
2. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease;Mullins;Cancer Res,2004
3. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells;Yamamoto;J Leukoc Biol,2000
4. CXCR3 is induced early on the pathway of CD4+ T-cell differentiation and bridges central and peripheral functions;Rabin;J Immunol,2003
5. Phase I trial of a melanoma vaccine with gp100(280 to 288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes;Slingluff;Clin Cancer Res,2001
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献